Arrowhead Clinic Chiropractor Marietta is highlighting the critical importance of seeking immediate medical attention for ...

For benign paroxysmal positional vertigo (BPPV), the overall positive rate for positional tests is significantly higher in the morning than in the evening, according to a study published online Oct. 6 ...

Vestibular migraine is a type of migraine disorder marked by balance problems. It affects up to 3 percent of the population, though it’s often misdiagnosed and probably underdiagnosed. Vestibular ...

How one woman went from a severe alopecia areata diagnosis to finding the right prescription treatment for her—and getting ...

The FDA approved Lynkuet, a new nonhormonal menopause drug that reduces moderate to severe hot flashes and night sweats.

The FDA approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for the treatment of major depressive ...

Hope Medicine (HopeMed), a clinical-stage innovative biotech company, in collaboration with a joint research team from Peking ...

Boehringer recently reported positive results from the Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced NSCLC at ESMO 2025. The company is pursuing regulatory ...

The Food and Drug Administration (FDA) has approved Caplyta ® (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.

The decision to discontinue production was driven by business considerations rather than concerns about the product’s safety or effectiveness.

A new treatment for those suffering from "chronic" eczema is set to be available on the NHS within the next three months.

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...